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Abstract: Background: Cardiovascular disease is the leading cause of worldwide morbidity and
mortality. Several studies have demonstrated that specific probiotics affect the host’s metabolism and
may influence the cardiovascular disease risk. Objectives: The aim of this study was to investigate the
influence of an isoflavone-supplemented soy product fermented with Enterococcus faecium CRL 183
and Lactobacillus helveticus 416 on cardiovascular risk markers in moderately hypercholesterolemic
subjects. Design: Randomized placebo-controlled double-blind trial Setting: São Paulo State
University in Araraquara, SP, Brazil. Participants: 49 male healthy men with total cholesterol
(TC) >5.17 mmol/L and <6.21 mmol/L Intervention: The volunteers have consumed 200 mL of the
probiotic soy product (group SP-1010 CFU/day), isoflavone-supplemented probiotic soy product
(group ISP–probiotic plus 50 mg of total isoflavones/100 g) or unfermented soy product (group
USP-placebo) for 42 days in a randomized, double-blind study. Main outcome measures: Lipid
profile and additional cardiovascular biomarkers were analyzed on days 0, 30 and 42. Urine samples
(24 h) were collected at baseline and at the end of the experiment so as to determine the isoflavones
profile. Results: After 42 days, the ISP consumption led to improved total cholesterol, non-HDL-C
(LDL + IDL + VLDL cholesterol fractions) and electronegative LDL concentrations (reduction of
13.8%, 14.7% and 24.2%, respectively, p < 0.05). The ISP and SP have prevented the reduction
of HDL-C level after 42 days. The C-reactive protein and fibrinogen levels were not improved.
The equol production by the ISP group subjects was inversely correlated with electronegative LDL
concentration. Conclusions: The results suggest that a regular consumption of this probiotic soy
product, supplemented with isoflavones, could contribute to reducing the risk of cardiovascular
diseases in moderately hypercholesterolemic men, through the an improvement in lipid profile and
antioxidant properties.
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1. Introduction
Cardiovascular disease (CVD) is the leading cause of mortality around the world and
dyslipidaemic patients remain at high risk of vascular incidents [1]. Oxidative alterations on
low-density lipoproteins (LDL), resulting in oxidized LDL and electronegative LDL (LDL (´)), are also
related to atherogenic processes stimulated by the immune system components [2,3]. LDL (´) is
a modified LDL which was developed in response to its exposure to oxidizing agents (superoxide
anion, hydrogen peroxide, and enzymes), which is increased in patients with hypercholesterolemia
and coronary artery disease [4]. In the bloodstream, it exhibits immunogenic properties leading
to the generation of autoantibodies against LDL (´) [5]. However, the importance of anti-LDL (´)
autoantibodies in atherogenesis is controversial: the atherogenic role was supported by studies that
have found elevated concentrations of autoantibody against LDL (´) in patients suffering from
atherosclerosis [6]; antiatherogenic properties were evidenced by others that have found an inverse
relation between anti-LDL (´) autoantibodies and atherosclerosis development [7,8]. Fibrinogen
interferes in the blood viscosity, platelet aggregation, fibrin formation, and thus in coagulation and
fibrinolysis processes. Moreover, fibrinogen is an acute phase protein involved in a systemic response
to inflammation, and thus participating directly in the atherogenesis [9]. C-reactive protein (CRP) is an
acute phase protein whose concentration is increased in inflammatory states at the initial stages of
atherosclerotic plaque formation, and could predict future risk of sudden cardiac death in apparently
healthy individuals [10].
Prevention and management of hyperlipidaemia involve pharmacological treatment and changes
in the individual’s lifestyle, including practice of regular physical activity and specific diets [11].
Drugs used in the treatment of dyslipidemia are rather expensive and can produce severe side effects,
which might lead to therapy discontinuation [12]. Therefore, it is important to seek new alternative
strategies to modulate the lipid profile and reduce the CVD risk.
Strong evidences have suggested that the dietary intake of functional foods, such as soybean
derivatives and probiotics, could positively modulate blood lipid levels [13–15]. Soy protein and
isoflavones have been associated with the decrease of cholesterol and cardioprotective effects through
anti-inflammatory and hormonal mechanisms [16–18]. In addition, a few studies have reported
that the protective effect of soy isoflavones is limited or more pronounced in equol-producing
individuals [19]. On the other hand, functional foods containing probiotics have also emerged as a
potential dietary way of reducing plasma cholesterol levels [14,20]. Our research group previously
showed that Enterococcus faecium CRL 183 is able to reduce cholesterol by 53.85% in an in vitro study [21].
In further studies it was demonstrated that a soy drink, fermented with E. faecium CRL 183, significantly
improves the lipid profile in animal and clinical trials [22,23]. However, during the processing of soy
beverages the total isoflavone content is drastically reduced [24]. In order to minimize this problem,
the fermented soy product was supplemented with an isoflavone mixture (Isoflavin®, Galena: 4.7%
genistin, 11.3% genistein, 5.5% daidzin, 17.8% daidzein, 2.0% glycitin and 1.0% glycitein) to obtain
approximately the same amount of content of in the whole bean. This new fermented product was
able to reduce the blood’s lipid levels, inhibit the atherosclerosis development and modulate the fecal
microbiota of rabbits with induced hypercholesterolemia [25–27].
Earlier studies of our research group suggest that the daily consumption of soy drink fermented
with E. faecium CRL 183 with isoflavones may reduce the CVD risk in animal models. Therefore, it was
hypothesized that the antioxidant properties of isoflavones would be able to enhance the beneficial
effect of the probiotic fermented soy product in clinical trials. In this context, the aim of the present
study was to investigate the influence of an isoflavone-supplemented soy product, fermented with
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E. faecium CRL 183 and Lactobacillus helveticus 416 on the lipid profile and other biomarkers of CVD
risk in moderately hypercholesterolemic subjects.
2. Experimental Section
2.1. Subjects and Study Design
Sixty-nine men, aged between 37 and 57 years, were initially recruited from the School of
Pharmaceutical Sciences, Sao Paulo State University, Araraquara, SP, Brazil, with permission of
the local ethics committee (Committee of Ethics in Research of the School of Pharmaceutical Sciences,
Sao Paulo State University—approval protocol n.062007). The Local Committee follows the standards
of the National Research Ethics Commission, linked to the Ministry of Health and, the study
was conducted according to the guidelines laid down in the Declaration of Helsinki. A written
informed consent was obtained from all subjects. The sample size was calculated using the t test for
independent samples (Biostat 4.0). The data were obtained from a pilot study which was previously
conducted by our research group. The primary outcome measure was change in the serum’s total
cholesterol. By assuming that α = 0.05 and 1-β = 0.8, a minimum of 15 participants was required.
The inclusion criteria were: men with total cholesterol (TC) >5.17 mmol/L and <6.21 mmol/L, and
going on a traditional normocaloric diet (<30% of total energy as fat, 15%–18% as protein, 52%–55%
as carbohydrates). The exclusion criteria were: history of chronic health problems (kidney, liver,
cardiovascular, immunodeficiency or inflammatory bowel disease), consumption of any kinds of
supplements, current use of hypolipemiant medication; utilization of probiotic products or antibiotic
medication within the previous 3 months, and vegan dietary or soy and its derivatives consumption
as a primary protein source. In this study, only male volunteers were recruited so as to exclude the
natural protective effect of endogenous 17-β-estradiol (human female hormone). Asian descendants
men were not allowed due to possible ethnic-specific health effects of isoflavones. Twelve participants
were excluded because they did not meet the study’s inclusion/exclusion criteria and eight dropped
out of the study.
2.2. Experimental Design and Diets
A placebo-controlled double-blind was designed and the 49 volunteers were randomly divided
into 3 groups: Group ISP (n = 17) which received the fermented soy product with isoflavones, Group
SP (n = 17) with the fermented soy product, and Group USP with the unfermented soy product
(placebo; n = 15). Randomization was obtained by computer software and the products were coded
with a three-digit number by an independent laboratory technician. The treatment and placebo product
were packaged likewise and with the same appearance. Neither the investigators, nor the volunteers
were informed about the identity of the studied products. Each volunteer consumed 200 mL of their
respective drinks for 42 days. During the study, the subjects were encouraged to lead their lives as
they normally would, with no change in their regular diets or physical activity. Dietary intake was
recorded for three non-consecutive days to assess their habitual diet.
The fermented soy product was manufactured at UNIVERSOJA (Production and Development
Unit for Soybean Derivatives) in the Food and Nutrition Department of the School of Pharmaceutical
Sciences, UNESP at Araraquara (SP, Brazil), following the method described by Rossi et al. [28].
The chemical composition of each product is presented in Table 1. Soymilk (82.0%), soy oil (2.6%)
and lactose (2.0%) were homogenized and heated to 70 ˝C. Following this procedure, sucrose (10.0%),
skim milk (3.5%) and gelatin (0.5%) were added, and the mixture was afterwards homogenized and
pasteurized (95 ˝C for 5 min). The fermentation (E. faecium CRL183 and L. helveticus 416; 3% v/v) was
conducted at 37 ˝C until the product reached a pH of 4.4–4.5. The products were stored at 7 ˝C and all
analyzes were conducted after 7 days.
Only E. faecium CRL183 was previously confirmed as probiotic in in vitro and in vivo studies.
L. helveticus 416 was used due to its technological properties (fermentation process improvement).
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Table 1. Composition of the different soy-based products.
Composition in 100 g of Soy Product ISP SP USP
Protein (g) 3.85 ˘ 0.00 a 3.90 ˘ 0.00 a 3.85 ˘ 0.04 a
Fat (g) 2.26 ˘ 0.09 a 2.30 ˘ 0.08 a 2.32 ˘ 0.02 a
Carbohydrate (g) 10.06 ˘ 0.11 a 9.70 ˘ 0.15 a 9.93 ˘ 0.16 a
Ash (g) 0.90 ˘ 0.00 a 0.90 ˘ 0.07 a 0.90 ˘ 0.00 a
Moisture (g) 82.93 ˘ 0.17 a 83.20 ˘ 0.00 a 83.00 ˘ 0.16 a
Isoflavones (mg) 51.26 ˘ 1.12 a 8.04 ˘ 0.01 b 8.03 ˘ 0.07 b
ISP = isoflavone-supplemented soy product; SP = soy product; USP = unfermented soy product (placebo).
Values represent mean ˘ SD (n = 3). Statistical comparison of products (ISP, SP, USP) by ANOVA followed by
a Tukey’s post hoc test. Means with identical lowercase superscript letters (a or b) in the same line do not differ
significantly from each other (p < 0.05).
Isoflavin® (Galena, Brazil) was added to the soy product before the fermentation, so as to reach
50 mg (total isoflavones) per 100 g, in order to yield the isoflavone-supplemented soy product.
Isoflavin® contains 40.77% total isoflavones, which consist of 1.81% genistin, 5.36% genistein,
2.91% daidzin, and 29.38% daidzein. Thus, it was added 122.64 mg of Isoflavin®, corresponding
to: 2.22 mg of genistin, 6.57 mg of genistein, 3.57 mg of daidzin, and 36.03 mg of daidzein per 100 g of
fermented product.
The placebo (non-fermented soy product) was prepared by chemical acidification (with food-grade
lactic acid) of the soy product’s basic mixture (without bacterial culture or isoflavones).
Both the soy product and the isoflavone-supplemented soy product exhibited probiotic
microorganism counts between 108 and 109 CFU (colony-forming unit)/mL.
The products were freshly produced every week, refrigerated and delivered to each volunteer in
plastic vials labeled with their manufacture and expiration date.
2.3. Data Collection
The subject’s body mass index (BMI) was calculated using the following equation:
BMI = weight (kg)/height (m2). Anthropometric data was gathered by using standard techniques.
Blood samples were collected after an overnight fast (12 h) at baseline (T0), after 30 (T30) and
42 (T42) days of the study. For measuring plasma LDL(-) and anti-LDL(-) autoantibody concentrations,
the blood was drawn into evacuated tubes (Becton Dickinson, Rutherford, NJ, USA) containing
EDTA (1 g/L) and centrifuged for 10 min at 3500ˆ g at 4 ˝C (Sorvall, Kendro Laboratories Products,
Ashville, USA). After the plasma separation, 1.0 mmol/L phenylmethylsulfonyl fluoride (Sigma
Chemical, St Louis, MO, USA), 2.0 mmol/L benzamidine (Sigma Chemical), 2.0 mg/L aprotinin
(Sigma Chemical), and 20.0 mmol/L BHT (Sigma Chemical) were added to the samples. For fibrinogen
determination, the plasma was collected in tubes containing sodium citrate (38 g/L) and centrifuged at
1500ˆ g for 15 min at 4 ˝C. Blood for lipid profile and C-reactive protein determination was collected
using evacuated tubes, kept at room temperature and centrifuged at 3500ˆ g for 10 min. One 24-h
urine sample was collected at baseline and at the end of the experiment (T42) to analyze its isoflavone
profile. Fecal samples were collected at days 0, 30 and 42 of the study to determine the gastrointestinal
resistance of the probiotic strain. All serum, plasma, feces and urine samples were stored at ´80 ˝C
until the analysis.
2.4. Lipid Profile
The serum levels of TC, high-density lipoprotein cholesterol (HDL-C) and triglycerides (TG)
were assayed in each volunteer, with the aid of specific enzyme kits. The TC was measured by the
cholesterol fast color method [29]. The HDL cholesterol was estimated by selective precipitation
of lipoproteins [30] and then by TC method in the supernatant. The triglyceride fast color method
was used to measure the triglycerides [31]. The LDL-C (low-density lipoprotein cholesterol) was
determined by Friedewald’s equation LDL-C = TC ´ HDL-C ´ TG/5 [32]. The Non-HDL cholesterol
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was calculated by subtracting HDL-C from TC, representing the LDL + IDL + VLDL cholesterol
fractions [33,34]. The concentrations of all lipids parameters were expressed in mmol/L.
2.5. LDL (´) and Anti-LDL (´) Autoantibodies
The LDL fraction was separated by ultracentrifugation as described by Lobo et al. [35].
Concentrations of LDL (´) were detected in the blood plasma by ELISA using two anti-electronegative
LDL monoclonal antibodies (mAb 1A3 and mAb 2C7), according to Faulin et al. [36]. Briefly,
ninety-six-well flat-bottom polystyrene plates (Costar, Corning, Inc., Teterboro, NY, USA) were coated
with 50 µL mAb 1A3 (1 µg/well) in a carbonate-bicarbonate buffer (pH 9.4, 0.1 M) and incubated
overnight at 4 ˝C. Subsequently, each microplate was washed three times with a phosphate-buffered
saline solution (PBS; Tris-HCl 50 mM and NaCl 150 mM, pH 7.4) containing Tween 20 (0.5%) and
blocked with 5% nonfat dry milk for 2 h at 37 ˝C. The microplates were then washed once more and
incubated with 50 µL plasma for 2 h at 37 ˝C. The plates were washed and incubated with 2C7 anti-LDL
monoclonal antibody biotinylated for 2 h at 37 ˝C. After washing, the microplates were incubated with
a streptavidin- HRP (horseradish peroxidase) conjugate (Rockland Immuno- chemicals for Research,
Gilbertville, PA, USA) for 1 h at 37 ˝C. Then, the OPD substrate solution was added to each well.
The absorbance intensity was determined immediately using a microplate reader (SpectraCount
Microplate Photometer, Packard Instruments Company, Downers Grove, IL, USA). The calibration
curve was made with the LDL obtained from human plasma. All samples and standards were run in
triplicate. The intra and inter-assay variations for the ELISA test were 8% and 15%, respectively.
Anti-LDL (´) autoantibodies were determined according to Faulin et al. [29]. Ninety-six-well flat
bottom polystyrene plates were coated with 1 µg/mL of LDL(´), overnight at 4 ˝C. The plates were
washed 3 times with PBS, pH 7.4, containing 0.05% Tween 20. The plates were blocked by the addition
of PBS containing 2% non-fat dry milk and 0.01% Tween 20 for 90 minutes at 37 ˝C, followed by
washing, as stated above. Plasma in PBS containing 1% non-fat milk and 0.01% Tween 20 was added in
the plates and incubated for 1 1/2 h at 37 ˝C. Afterwards, the plates were washed and incubated with
anti-human IgG-conjugated to horseradish peroxidase (Bio-Rad) for 1 h at 37 ˝C. Then, the washed
plates were incubated with 3, 31, 5, 51 tetramethylbenzidine (TMB, Sigma Chemical) for 10 min at
37 ˝C. The reaction was interrupted by adding 0.5 mol/L sulfuric acid, and the absorbance at 450 nm
was measured by spectrophotometry, using a plate reader (Synergy™ Mx, Biotek Instruments Inc,
Winooski, VT, USA).
2.6. C-Reactive Protein (CRP) and Fibrinogen
The concentration of fibrinogen was assayed by the Gauss method, using a commercial kit
(Wiener Laboratorios A.S.I.C., Rosario, Argentina).
The C-reactive protein was analyzed in the Clinical Laboratory of the University Hospital at the
University of Sao Paulo (USP) using the BN II Systems (Siemens) by immunonephelometry method,
with detection limit of 1.43 nmol/L (0.15 mg/L) according to manufacturer’s instructions.
2.7. Isoflavone Profile
The extraction of isoflavones, including daidzin, genistin, daidzein, genistein, and equol, was
performed according to Rossi et al. [24]. Isoflavone standards were purchased from Sigma Chemicals
Co. (St. Louis, MO, USA) and prepared in high performance liquid chromatography (HPLC)
grade ethanol. The isoflavone quantification was carried out through a HPLC system (Shimadzu®,
Kyoto, Japan), which is equipped with an auto sampler (SIL-10AF), a diode array ultraviolet
(UV) visible detector (SPD-10MA), a quaternary pump, a vacuum degasser, and a Hypersil ODS
C18 (250 mm ˆ 4.6 mm) reverse-phase column (Supelco®). All reagents used in the isoflavone
extraction and HPLC analyses were filtered through a 0.22 µm or 0.45 µm membrane (hydrophilic
Polytetrafluoroethylene—PTFE—Millipore). The HPLC isocratic elution was used to isolate the
isoflavones for detection and was composed of acetic acid-water 60% (2:98 v/v—solvent A) and
Nutrients 2016, 8, 52 6 of 18
methanol-acetonitrile 40% (80:20 v/v—solvent B), set at a flow rate of 1.1 mL/min, during 40 min.
The diode array UV-visible detector was set at dual wavelengths of 262 nm to detect daidzin, genistin,
daidzein and genistein and 280 nm for equol detection. The identification of isoflavones was confirmed
by the HPLC retention time and UV spectral analysis.
2.8. Gastrointestinal Resistance of E. faecium
The fecal samples (1.0 g) were homogenized, suspended in peptone water (9.0 mL) and serially
diluted. Enterococcus spp. colonies were isolated using the KF Streptococcus agar (Acumedia, Baltimore,
MD, USA) with incubation at 37 ˝C for 48 h. Colonies with distinct morphologies were picked
out and transferred onto the Bile Esculin Azide agar for confirming of the Enterococcus genus
(Acumedia) [37–39]. The API Strep 20 (Biomérieux, Marcy l’Etoile, France) was used to identify
the enterococci species. Colonies identified as E. faecium were cultured on Tryptic Soy Broth (TSB,
Acumedia) for genomic DNA extraction. Enterococcus faecium species confirmation was performed by
Polymerase Chain Reaction (PCR) amplification of genomic DNA. The genomic DNA was extracted
by using a DNeasy kit (Qiagen, Valencia, CA, USA), according to manufacturer’s instructions. A pure
culture of E. faecium CRL 183 was included for comparison. 16S rDNA PCR amplification was
performed using the following primer combination: Enf 1 (1 (51-ATTACGGAGACTACACACTTTG-31)
and Ent 2 (51- TAGCCATAGAAGTTACATCAAG-31). These primers encode the 16S rRNA region
of E. faecium. The reaction mixture was composed of 1 µM of each primer, 100 ng of genomic DNA,
1.5 mmol/L MgCl2, 100 µmol of deoxynucleotides and 2 U of Taq DNA polymerase enzyme (final
volume was adjusted to 50 µL). The mixture was amplified using the following program: 30 cycles at
94 ˝C for 1 min, 56 ˝C for 30 s and 72 ˝C for 1 min and a final extension at 72 ˝C for 5 min. PCR products
were separated by electrophoresis in agarose gel (1.5% in TAE buffer—40 nmol/L Tris, 11% glacial
acetic acid, 1 mmol/L EDTA). A 1 kb Ladder Plus (Invitrogen, Life Technologies, Carlsbad, CA, USA)
was included as molecular size standard. Finally, the gels were stained with ethidium bromide and
photographed under UV illumination [39,40].
2.9. Statistical Analysis
Quantitative results were reported as mean ˘ SD. Normality and homogeneity were checked
before conducting further analyses. Parametric variables were analyzed by univariate analysis of
variance (ANOVA) followed by a Tukey’s post hoc test. The relation between the individual’s ability
to produce equol and the cardiovascular risk markers was analyzed by Pearson’s correlation test.
Statistical significance was declared when p < 0.05. All analyses were carried out with the BIOSTAT
statistical package.
3. Results
3.1. Study Population
The study groups’ age ranged between around 45 and 48 years, with BMI between 25 and
26 kg/m2 and waist-to-hip circumference ratio of around 0.90. At baseline, no significant difference
in anthropometric characteristics and food intake was observed between the experimental groups
(p < 0.05). The overall clinical status of the volunteers was satisfactory, two of them being hypertensive
(ISP and SP groups) and two having gastrointestinal diseases (ISP and SP) (Table 2).
No significant changes (p < 0.05) were observed in the anthropometric measurements of the
volunteers during the study period (data not shown). Clinical conditions, lifestyle and caloric intake
also remained unchanged during the protocol.
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Table 2. Clinical characteristics at baseline of the 49 men involved in the study.
Clinical Characteristics
Groups
ISP (n = 17) SP (n = 17) USP (n = 15)
Age (y) 48.1 ˘ 5.1 a 46.1 ˘ 6.1 a 45.4 ˘ 5.1 a
Height (m) 1.73 ˘ 0.08 a 1.75 ˘ 0.06 a 1.72 ˘ 0.07 a
Weight (kg) 76.7 ˘ 14.5 a 81.6 ˘ 15.6 a 78.0 ˘ 14.1 a
BMI (kg/m2) 25.65 ˘ 4.36 a 26.41 ˘ 4.88 a 26.26 ˘ 3.98 a
WHR 0.91 ˘ 0.06 a 0.90 ˘ 0.07 a 0.90 ˘ 0.05 a
Diabetes 0 0 0
Hypertension 1 (5.9%) 1 (5.9%) 0
Gastrointestinal diseases 1 (5.9%) 1 (5.9%) 0
Previous CVD 0 0 0
Smoking 3 (17.6%) 2 (11.8%) 3 (20.0%)
Values are mean˘ SD. Statistical comparison of groups (ISP, SP, USP) by ANOVA followed by a Tukey’s post hoc
test. Means with identical lowercase superscript letter (a) in the same line do not differ significantly from each
other (p < 0.05). ISP Group: individuals who consumed the isoflavone-supplemented soy product; SP Group:
individuals who consumed the soy product; USP Group: individuals who consumed the unfermented soy
product (placebo). BMI = Body mass index; WHR = waist–hip ratio; CVD = cardiovascular disease. Normal
values: BMI > 18.5 and <25 (kg/m2); WHR < 0.90 cm [41].
3.2. Lipid Profile
Only the subjects who consumed ISP showed a significant reduction of 13.8% ˘ 7.7% on the
basal levels of TC, throughout 42 days of study. Serum levels of HDL-C and triglycerides did not
differ significantly between groups in this study. At the end of the experimental protocol, there was
a reduction of 24.6% ˘ 8.6% (p < 0.05), 11.0% ˘ 4.8% (p = 0.171) and 8.1% ˘ 3.1% (p = 0.338) in the
HDL-C levels of groups USP, ISP and SP, respectively (Table 3). After 30 and 42 days of treatment,
ISP intake resulted in a decrease in the LDL-C (14.8% ˘ 9.7% and 13.5% ˘ 8.7%, respectively) and
non-HDL-C (15.5% ˘ 11.2% and 14.7% ˘ 10.3%, respectively) concentrations, but this effect was
significant only in comparison with the USP group (p < 0.05). At the end of the study, the TC-to-HDL-C
ratio was lower (p < 0.05) in the ISP group if compared to the USP group.
Table 3. Serum lipids levels during the experiment.
Time ISP (n = 17) SP (n = 17) USP (n = 15)
TC (mmol/L)
T0 5.47 ˘ 0.59 a,A 5.76 ˘ 1.02 a,A 5.60 ˘ 0.76 a,A
T30 4.65 ˘ 0.48 b,B 5.44 ˘ 0.93 a,A 5.52 ˘ 0.76 a,A
T42 4.72 ˘ 0.45 b,B 5.41 ˘ 0.86 a,A 5.50 ˘ 0.78 a,A
HDL-C (mmol/L)
T0 1.36 ˘ 0.22 a,A 1.38 ˘ 0.25 a,A 1.50 ˘ 0.28 a,A
T30 1.18 ˘ 0.23 a,A 1.33 ˘ 0.19 a,A 1.24 ˘ 0.38 a,A,B
T42 1.21 ˘ 0.22 a,A 1.28 ˘ 0.18 a,A 1.13 ˘ 0.38 a,B
LDL-C (mmol/L)
T0 3.23 ˘ 0.61 a,A 3.54 ˘ 0.92 a,A 3.14 ˘ 0.95 a,A
T30 2.75˘ 0.51 a,A 3.33 ˘ 0.84 a,A 3.41 ˘ 0.60 a,A
T42 2.79 ˘ 0.50 b,A 3.35 ˘ 0.80 a,b,A 3.51 ˘ 0.63 a,A
TG (mmol/L)
T0 1.91 ˘ 0.98 a,A 1.88 ˘ 0.88 a,A 1.97 ˘ 1.32 a,A
T30 1.57 ˘ 0.74 a,A 1.83 ˘ 0.89 a,A 2.18 ˘ 1.61 a,A
T42 1.55 ˘ 0.70 a,A 1.86 ˘ 0.93 a,A 2.15 ˘ 1.64 a,A
nHDL-C (mmol/L)
T0 4.11 ˘ 0.65 a,A 4.38 ˘ 1.12 a,A 4.08 ˘ 0.82 a,A
T30 3.47 ˘ 0.48 a,B 4.11 ˘ 0.98 a,A 4.28 ˘ 0.99 a,A
T42 3.50 ˘ 0.46 b,B 4.14 ˘ 0.92 a,b,A 4.37 ˘ 0.96 a,A
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Table 3. Cont.
Time ISP (n = 17) SP (n = 17) USP (n = 15)
TC/HDL-C
T0 4.11 ˘ 0.78 a,A 4.28 ˘ 0.90 a,A 3.80 ˘ 0.83 a,A
T30 4.07 ˘ 0.75 a,A 4.18 ˘ 0.90 a,A 4.92 ˘ 1.69 a,A
T42 4.00 ˘ 0.71 b,A 4.32 ˘ 0.83 a,b,A 5.47 ˘ 1.98 a,A
Values are mean ˘ SD. ANOVA followed by a Tukey’s post hoc test. Statistical comparison of groups (ISP, SP,
USP): means with identical lowercase superscript letters (a or b) in the same line do not differ significantly
(p < 0.05) from each other, in the same period. Statistical comparison of periods (T0, T30, T42): means with
identical uppercase superscript letters (A or B) in the same column do not differ significantly from each
other (p < 0.05), for the same parameter. TC: total cholesterol; LDL-C: low-density lipoprotein; HDL-C:
high-density lipoprotein; TC/HDL-C: total cholesterol to HDL-cholesterol ratio; TG: triglyceride; nHDL-C:
non HDL-cholesterol. ISP Group: individuals who consumed the isoflavone-supplemented soy product; SP
Group: individuals who consumed the soy product; USP Group: individuals who consumed the unfermented
soy product (placebo).T0: baseline; T30: 30 days of daily consumption of soy products; T42: 42 days of daily
consumption of soy products. Normal values for subjects at low or moderate risk: CT: <5.0 mmol/L; HDL-C:
>1.6 mmol/L (ideal); LDL-C: <3.0 mmol/L; TG: <1.7 mmol/L [41].
3.3. LDL (´) and Anti-LDL (´) Autoantibodies
LDL(-) levels in the ISP group were reduced after 30 (25.3% ˘ 9.9%) and 42 days (24.2% ˘ 11.1%)
of study in comparison with the baseline (p < 0.05). After 30 and 42 days of study, the concentration of
autoantibody against LDL (´) tended to be higher in subjects who consumed the fermented product
supplemented or not with isoflavones (Figure 1).
Nutrients 2016, 8, 52 8 of 18 
 
T0 4.11 ± 0.65 a,A 4.38 ± 1.12 a,A 4.08 ± 0.82 a,A 
T30 3.47 ± 0.48 a,B 4.11 ± 0.98 a,A 4.28 ± 0.99 a,A 
T42 3.50 ± 0.46 b,B 4.14 ± 0.92 a,b,A 4.37 ± 0.96 a,A 
TC/HDL-C    
T0 4.11 ± 0.78 a,A 4.28 ± 0.90 a,A 3.80 ± 0.83 a,A 
T30 4.07 ± 0.75 a,A 4.18 ± 0.90 a,A 4.92 ± 1.69 a,A 
T42 4.00 ± 0.71 b,A 4.32 ± 0.83 a,b,A 5.47 ± 1.98 a,A 
Values are mean ± SD. NOVA followed by a Tukey’s post hoc test. Statistical comparison of ro s 
(ISP, SP, USP): me ns with identical lowe case superscript letters (a or b) in the same line do not differ 
signific ntly (p < 0.05) from each other, in the same period. Statistical comparison of periods (T0, T30, 
T42): means with identical uppercase superscript letters (A or B) in the same column do not differ 
significantly from each other (p < 0.05), for the same parameter. TC: total cholesterol; LDL-C: low-
density lipoprotein; HDL-C: high-density lipoprotein; TC/HDL-C: total cholesterol to HDL-
cholesterol ratio; TG: triglyceride; nHDL-C: non HDL-cholesterol. ISP Group: individuals who 
consumed the isoflavone-supplemented soy product; SP Group: individuals who consumed the soy 
product; USP Group: individuals who consumed the unfermented soy product (placebo).T0: baseline; 
T30: 30 days of daily consumption of soy products; T42: 42 days of daily consumption of soy products. 
Normal values for subjects at low or moderate risk: CT: <5.0 mmol/L; HDL-C: >1.6 mmol/L (ideal); 
LDL-C: <3.0 mmol/L; TG: <1.7 mmol/L [41]. 
3.3. LDL (‒) and Anti-LDL (‒) Autoantibodies 
LDL(‒) levels in the ISP group were reduced after 30 (25.3% ± 9.9%) and 42 days (24.2% ± 11.1%) 
of study in comparison with the baseline (p < 0.05). After 30 and 42 days of study, the concentration 
of autoantibody against LDL (‒) tended to be higher in subjects who consumed the fermented 
product supplemented or not with isoflavones (Figure 1). 
 
(a) 
 
(b) 
Figure 1. Electronegative low-density lipoproteins (LDL) (LDL (´)) (a) and anti-LDL (´) autoantibodies
(b) after 30 and 42 days of study (changes from baseline). * Different from the baseline (p < 0.05). ISP
Group: individuals who consumed the isoflavone-supplemented soy product; SP Group: individuals
who consumed the soy product; USP Group: individuals who consumed the unfermented soy product
(placebo). T0: baseline; T30: 30 days of daily consumption of soy products; T42: 42 days of daily
consumption of soy products.
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3.4. Fibrinogen and C-Reactive Protein
At the end of the study (T42), there was a reduction in the fibrinogen concentration of volunteers
who received the SP (T0: 9.22 ˘ 1.25; T42: 8.60 ˘ 1.10 µmol/L) and ISP (T0: 9.10 ˘ 1.77; T42:
8.83 ˘ 1.16 µmol/L), respectively. On the other hand, the group that ingested USP exhibited increased
levels of fibrinogen (T0: 8.32 ˘ 1.27; T42: 8.56 ˘ 0.90 µmol/L). However, these results were not
statistically significant (p < 0.05) (Figure 2a). The C-reactive protein levels of ISP (T0: 9.05 ˘ 6.955; T42:
8.86 ˘ 6.38 nmol/L) SP (T0: 11.43 ˘ 8.48; T42: 9.24 ˘ 5.14 nmol/L) and USP (T0: 12.95 ˘ 8.57; T42:
13.33 ˘ 12.19 nmol/L) groups did not differ (p < 0.05) during the experimental period (Figure 2b).
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Figure 2. Fibrinogen (a) and C-reactive protein (b) concentrations during clinical trial. Values are
mean ˘ SD. Mea s ithout significant differences between groups for the same sampling eriod of
the study and without significant differences between samp ing periods for the same st dy group
(p < 0.05). ISP Group: individuals who consumed the isoflavone-supplemented soy product; SP Group:
individuals who consumed the soy product; USP Group: individuals who consumed the unfermented
soy product (placebo). T0: baseline; T30: 30 days of daily consumption of soy products; T42: 42 days of
daily consumption of soy products.
3.5. Urine Isoflavones
At the end of the experimental protocol, subjects who ingested ISP showed a total isoflavone level
that was 5.09 and 7.50 times greater than that of those who consumed the SP and USP, respectively
(Table 4). The volunteers were defined as “equol producers” when the log10-trzansformed urinary
S-equol: daidzein ratio was greater than ´1.75 [42]. Thus, equol was only identified in the ISP group,
and 66.7% of volunteers were classified as “equol producers”. There was no significant correlation
between individual ability to produce equol and the cardiovascular risk markers analyzed in this study
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(Pearson’s correlation, p < 0.05: CT = ´0.0668; HDL-C= ´0.0426; LDL-C= 0.4636; autoantibody against
LDL (´) = ´0.3831; CRP = 0.3149; and fibrinogen = 0.4754), except for LDL (´) = ´0.6938.
Table 4. Urine isoflavone profile of volunteers from different groups at the end of study (42 days).
Isoflavones (µmol/L) ISP (n = 17) SP (n = 17) USP (n = 15)
Daidzein 70.09 ˘ 25.21 a 13.02 ˘ 0.67 b 6.37 ˘ 1.9 c
Equol 5.24 ˘ 2.68 nd nd
Genistein 23.42 ˘ 7.88 a 6.18 ˘ 0.11 b 6.55 ˘ 0.41 b
Total 75.75 ˘ 35.78 a 19.20 ˘ 0.79 b 12.92 ˘ 0.60 c
Values are mean ˘ SD. Statistical comparison of groups (ISP, SP, USP) by ANOVA followed by a Tukey’s post
hoc test. Means with identical lowercase superscript letter (a, b or c) in the same line do not differ significantly
from each other (p < 0.05). Statistical comparison between groups: means with identical lowercase superscript
letters in the same line do not differ significantly (p ď 0.05). ISP Group: individuals who consumed the
isoflavone-supplemented soy product; SP Group: individuals who consumed the soy product; USP Group:
individuals who consumed the unfermented soy product (placebo).
3.6. E. faecium Gastrointestinal Survival
In general, there was an increase in the E. faecium population in the ISP and SP groups (Table 5).
Table 5. Enterococcus species (%) isolated from the feces of volunteers in 0, 30 and 42 days of the
experimental protocol.
Treatments
Enterococcus Species
T0 T30 T42
ISP
E. faecium 48.36% E. faecium 93.97% E. faecium 96.09%
E. faecalis 30.19% E. durans 6.03% E. durans 3.91%
E. durans 21.45%
SP
E. faecium 54.55% E. faecium 83.00% E. faecium 83.00%
E. gallinarum 18.55% E. durans 17.00% E. durans 17.00%
E. durans 26.90%
USP
E. faecium 52.80% E. faecium 50.30% E. faecium 45.10%
E. durans 20.07% E. gallinarum 25.80% E. gallinarum 30.10%
E. faecalis 7.13% E. durans 23.90% E. durans 24.80%
ISP Group: individuals who consumed the isoflavone-supplemented soy product; SP Group: individuals
who consumed the soy product; USP Group: individuals who consumed the unfermented soy product
(placebo). SP: individuals who consumed soy product; Group USP: individuals who consumed unfermented
soy product (placebo).
The PCR amplification (Figure 3) indicated that, at the beginning of the study (T0), approximately
50% of Enterococcus spp. colonies isolated from volunteers of different groups were confirmed as
belonging to the E. faecium species. At the end of the study, 96.09% and 83.00% of the colonies isolated
from volunteers of ISP and SP groups, respectively, were confirmed as E. faecium. Nevertheless, only
45.10% of the colonies from the USP group were E. faecium. PCR products obtained from the genomic
DNA of the pure culture of E. faecium CRL 183 indicated that species isolated from the volunteer‘s
feces belong to the CRL 183 strain.
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4. Discussion
At the beginning of the study all groups of volunteers had average levels of TC above 5.18 mmol/L,
LDL-C between 3.14 and 3.54 mmol/L, HDL-C above 1.29 mmol/L and TG higher than 1.69 mmol/L.
It is important to point out that no significant baseline differences were observed (p < 0.05) for any of
the evaluated lipid parameters, which e abled a comparison b twe n groups during the study.
After 42 days, the groups’ comparison showed that the ISP presented l wer concentrations of TC
(4.72˘ 0.45 mmol/L), LDL-C (2.79˘ 0.50 mmol/L), non-HDL-C (3.50˘ 0.46 mmol/L) and CT/HDL-C
ratio (4.11 ˘ 0.78), differing significantly from the placebo group (USP) in all these parameters, and
only in TC from the SP group. The fermented soy product, either being supplemented with isoflavones
or not, also prevented the reduction of HDL-C during the experimental protocol.
In a previous study, Rossi et al. [23] found that subjects who received the same fermented product
without supplementation (SP) showed unchanged TC and LDL-C concentrations and increased HDL-C
levels by 10% throughout 6 weeks of intervention. The differences between the results of the previous
study and th se in the present investigation can be explained by the clinical characteristics of the
participants, since Rossi et al., evalua ed normocholesterolemic men
Several ot er studies have bee conducted in order to verify the effects of probiotic
microorganisms in blood lipids, but the results are still controversial. Naruszewicz et al. [43] concluded
that the ingestion of a drink containing Lactobacillus plantarum 299v promotes a positive change
(LDL-C = ´12%; HDL-C = 10%) in plasma lipid levels in male smoking individuals. Hlivak et al. [44]
reported that the consumption of E. faecium M-74 capsules associated with 50 µg of selenium led
to a decrease in TC (12%) and LDL-C (20%). In a clinical study conducted by Ejtahed et al. [45],
the ingestion of yoghurt (300 g), produced with Lactobacillus acidophilus and Bifidobacterium lactis
was able to decrease TC and LDL-C levels. Capsules c ntaining three strains of L. plantarum (CECT
7527, 7528 and 7529; 1.2 ˆ 109 CFU) also promoted a reduc ion of TC levels [46]. On the other hand,
the administration of Lactobacillus paracasei LTH 2579 [47], Lactobacillus fermentu (PCC®) [48] and
Lactobacillus rhamnosus GG (LGG) [49] did not result in a hypocholesterolemic effect. The discrepancies
observed in scientific literature may be due to the used microorganism strains, the population
chosen for the study (normo or hipercholesterolemic), the vehicle of probiotic administration and the
protocol duration.
The mechanisms of hypolipemiant action of probiotics involves the assimilation of cholesterol,
deconjugation of bile salts, fermentation of non-digestible carbohydrates from the diet producing
short-chain fatty acids (SCFA), and microbiota modulation [20,50,51].
Chen et al. [50] evaluated the effect of Lactobacillus rhamnosus hsryfm 1301 or its fermented milk
on the intestinal microbiota and its relation with the serum lipids profile in a hyperlipidemic rat model.
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The results showed that the microbiota and lipid profile were improved after probiotic intervention.
A positive correlation between Ruminococcus spp. and triglycerides; Dorea spp. and TC and LDL-C;
and between Enterococcus spp. and HDL-C was observed. On the other hand, Butyrivibrio spp. was
negatively correlated with TC and LDL-C (p < 0.05), since this bacterial genus has activity of linoleate
isomerase, which could decrease the mRNA expression of sterol regulatory element-binding protein
(SREBP)-1c.
Oxidative modifications in LDL levels are usually related to an inflammatory process which is
associated with atherosclerosis. Particles of LDL (´) induce the expression of adhesion molecules to
leukocytes, leading their infiltration in the arterial wall. Monocytes differentiate into macrophages
with “scavenger” receptor properties that internalize lipid particles and promoting the ateroma
formation [4,52]. LDL (´) also induce the formation of autoantibodies reactive to LDL (´), which
have an uncertain role in the formation of the atherosclerotic plaque. Lobo et al. [35] reported that the
anti-LDL (´) IgG level were negatively correlated with inflammation marker concentration (TNF-α,
ICAM-1 and VCAM-1) in hemodialysed patients. Grosso et al. [53] showed that the immunization with
anti-LDL (´) monoclonal antibody reduced the free LDL (´) levels in the bloodstream and prevented
their atherosclerotic action. This effect could be due to the formation of immune complexes to LDL (´)
that neutralize the LDL (´) particles.
In the present study, the ISP consumption significantly reduced the LDL (´) concentrations if
compared to the baseline period. A trend of elevation on the levels of anti-LDL (´) autoantibodies was
observed in the ISP and SP groups, but this effect was not significant (p < 0.05). It can be assumed that
LDL (´) would stimulate the production of anti-LDL (´) autoantibodies, and the posterior formation
of immune complexes to LDL (´), which could be involved in the reduction of LDL (´) levels in the
volunteers. However, the results of the present study do not allow the definition of the exact role
of these markers in CVD, because all volunteers were hypercholesterolemic and had no diagnosed
coronary heart disease.
The lipid-lowering potential of isoflavones has been extensively studied and the results
are not uniform. Studies with hypercholesterolemic men showed a significant reduction of TC,
non-HDL-C [54] and LDL-C [55] after consumption of isolated soy protein containing varying amounts
of isoflavones. By analyzing 22 clinical studies, Sacks et al. [56] found that the combination of soy
protein and isoflavones was able to reduce approximately 3% of LDL-C level. However, other studies
did not demonstrate the beneficial effect of isoflavones on serum lipids. In this line, Hodgson et al. [57]
found that the administration of 55 mg of isoflavones in tablet did not significantly alter the levels of
serum lipids after 8 weeks of study. West et al. [58] concluded that ingestion of the 25 g of soy protein
containing 90 mg of isoflavones for 6 weeks resulted in a lipid profile improvement of the volunteers.
Isoflavones can improve the lipid profile and reduce the risk of cardiovascular disease by
estrogenic and non-estrogenic-related mechanisms. 17-β-estradiol enhance nitric oxide bioactivity
and modulate lipoprotein levels. Estrogen–estrogen receptor complexes act as transcription factors
that promote gene expression with vascular effects (response to injury and regulation of vasomotor
tone) related to cardioprotective properties [59]. Considering that isoflavones are structurally
similar to the 17-β-estradiol (human female hormone), they can bind to estrogen receptors (ER)
and have estrogen-like activities. The cardioprotective effect of isoflavones by estrogenic and
non-estrogenic-related mechanisms include: decrease in LDL cholesterol level, modulation of immune
system (inhibition of pro-inflammatory cytokines, cell adhesion proteins and inducible nitric oxide
production), protection of LDL oxidation, inhibition of platelet aggregation and improvement of
vascular reactivity [60]. The antioxidant effect are derived from the ability of scavenge radicals, chelate
metals and improvement of activities of antioxidant enzymes (superoxide dismutase, catalase and
glutathione peroxidase) [61]. Isoflavones can also modulate cholesterol metabolism, promoting hepatic
cholesterol catabolism [62].
The main soy isoflavones are in the glycosidic (genistin, daidzin and glycitin) or aglycone
(genistein, daidzein and glycitein) form, and the latter shows diagnosed higher bioavailability and
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associated biological effects. Daidzein and genistein exhibit more pronounced lowering effects of
cholesterol if compared to their respective glucosides forms [61]. It is noteworthy that the glycosidic
isoflavones are hydrolysed in the small intestine to the aglycone form and the metabolization efficiency
depends on the intestinal microbiota composition. The hypotheses to explain the differences in the
results obtained with isoflavones intake include: the amount and composition of the isoflavone mixture
and the individual capacity to metabolize daizein to equol, which is a metabolite that exhibits a potent
antioxidant effect in vivo [63].
The isoflavone recovery in the urine was 24.80% ˘ 7.89%, 31.03% ˘ 0.93% and 21.11% ˘ 3.11% for
groups ISP, SP and USP, respectively, with daidzein being eliminated at higher concentrations. The low
recovery of isoflavones could be explained by their metabolites production, which was not determined
in the present study. It is also important to note that the excretion of daidzein in the SP group was
significantly greater than that of group USP. These results suggest that the used lactic acid bacteria
(E. faecium CRL 183 and L. helveticus 416) and/or metabolites produced during the fermentation can
influence the conversion of isoflavone glucosides into aglucones.
Only 20% to 50% of the adult human population is able to produce equol after ingesting
pure isoflavones or soy-based foods [64–67]. The individual variation in the intestinal microbiota
composition and genetic predisposition are related to the presence of equol producers or non-producers
in populations with similar diets containing isoflavones [68]. In the present study, the percentage of
equol producers in the group that consumed ISP was superior to that presented in scientific literature
(66%) (data not shown). However, it was not possible to determine whether the individual capacity
to produce equol was affected by the ingestion of the product or due to the presence of the probiotic
microorganism, since at the beginning of the experiment (T0), the volunteers did not consume foods
with a significant source of isoflavones and the basal levels of these substances in urine have not
reached the detection limit of the method.
Wong et al. [69] studied the relations between equol production after regular consumption of
soy foods and lipid profile modulation. The results showed that soy foods reduced LDL-C in equol
producers and non-producers. However, HDL-C concentrations were higher in volunteers that are
able to produce equol. A correlation between improved lipid profile and equol production was not
observed in the present study. Nevertheless, equol production by subjects in the ISP group was
inversely correlated with the LDL (´) profile, indicating that the antioxidant capacity of this metabolite
could reduce the susceptibility to oxidation of this lipoprotein. The mechanism related to this effect
involves the inhibition of superoxide (O2) production that enhances the levels of free NO, which
prevents LDL modification [70].
The probiotic microorganisms should reach the intestine in a viable form to promote their
beneficial effects. The exposure to the gastrointestinal environment, which includes stomach acid,
bile salts and enzymes, represents the main survival hurdle for the probiotic bacteria [71], being
necessary to evaluate the resistance of individual strains under these conditions. In the present study,
probiotic E. faecium CRL 183 resistance was evaluated by biochemical and molecular tests. Colonies
with positive identification of Enterococcus genus by the API 20 Strep test were submitted to PCR using
a species-specific primer combination (Enf 1 and Ent 2) to amplify the 16S rRNA gene region from
the genomic DNA of E. faecium CRL 183, thus generating two amplification products: one of 200 bp
and another of 300 bp. The observation of two bands (200 bp and 300 bp) is in agreement with the
results obtained by Sivieri et al. [39] and Bedani et al. [37], who evaluated the viability of E. faecium
CRL183 in rats that receive the probiotic pure culture or a fermented soy product, during 30 weeks and
30 days, respectively. Langa et al. [40], using the Enf 1—Ent 2 primers, obtained two DNA bands after
amplification from the other strains of E. faecium (V8, HA1 and CH3): a 300-bp band and a unexpected
second band of 400 bp. It is interesting to note that the E. faecium CRL39 amplification demonstrated
the same result, while most E. faecium found in the feces of volunteers who consumed the test products
(ISP and SP) exhibited similar PCR products obtained from the genomic DNA of the pure culture
of E. faecium CRL 183. This result is an indicative that the probiotic microorganism used in the soy
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products, either supplemented or not with isoflavones, can survive to the adverse conditions of the
human gastrointestinal tract, furthermore, it could also assist in the intestinal microbiota modulation,
collaborating with the observed lipid-lowering effect.
5. Conclusions
The results of the present study suggest that the regular consumption of isoflavone-supplemented
soy product fermented with E. faecium CRL 183 and L. helveticus 416 could contribute to a reduction of
CVD risk markers in moderately hypercholesterolemic men, by lipid profile improvement, besides
reducing the oxidation of LDL particles. The beneficial health effects observed herein probably involve
a combination of antioxidant properties from isoflavones and the anti-inflammatory action of the
probiotic strain. It is important to emphasize that these results must be considered cautiously in case
of a female population, due to the estrogenic effects of isoflavones.
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